Daewoong Pharmaceutical is pushing to shift from a drug-centered business structure to a healthcare corporations that connects and manages public health data.
Daewoong Pharmaceutical held a kickoff ceremony on the 5th, reviewed last year's business performance, and shared its organizational operating methods and mid- to long-term business direction, it said. The company presented changes in organizational culture and work methods as a core pillar of its growth strategy.
Chief Executive Lee Chang-jae said at the kickoff ceremony, "Last year's results went beyond simple numbers and were the outcome of the attitude of members who reflected on the essence of work and sought to solve problems."
Daewoong Pharmaceutical said it achieved relatively stable results last year on the back of growth in key products such as Fexuclu, Envlo, and Nabota. In research and development (R&D), pipeline progress is also continuing. Versipherosin, being developed as the world's first treatment for idiopathic pulmonary fibrosis, is in global phase 2 trials, and the semaglutide microneedle patch has entered phase 1.
The Digital Healthcare sector is also establishing itself as one of the business pillars. The artificial intelligence (AI)-based inpatient bed monitoring system "Think" has been supplied to more than 13,000 beds, mainly at domestic medical institutions.
On this basis, Daewoong Pharmaceutical set a goal of making this year an inflection point for a shift in its business structure. Beyond developing and selling drugs, the focus is on building a healthcare platform that integrates and manages health data generated in hospitals and daily life.
Lee said, "We must move to a structure that encompasses post-treatment management," adding, "The goal is to consolidate health data to create a flow that connects prediction, prevention, diagnosis, treatment, and aftercare."
Daewoong Pharmaceutical plans to pursue a strategy to cultivate blockbuster products in parallel by advancing AI-based R&D and expanding its global business. Lee said, "We need an attitude that treats obstacles not as excuses but as targets to overcome," adding, "Only when learning and execution are repeated do meaningful results emerge."
Meanwhile, regarding organizational operations, Lee emphasized employees' work environment and growth structure. Lee said, "The starting point of organizational competitiveness is an environment where the commute is part of a natural routine rather than a burden and where people can focus on work without worrying about the future or their health."
Daewoong Pharmaceutical said it operates an evaluation and compensation system that emphasizes fairness and transparency, while introducing a career development program (CDP) that improves job fit through departmental transfers. It is also strengthening capabilities in the use of artificial intelligence and running health management programs for executives and employees.
Lee noted that without changes in the way people work, performance cannot be sustained. Lee said, "Past experiences and methods are no longer enough," adding, "We need a culture in which people, as owners of their tasks, decide for themselves the responsibility they assume and how they execute."